Fact-checked by Grok 2 weeks ago

Adrenergic receptor

Adrenergic receptors, also known as adrenoceptors, are a class of G protein-coupled receptors (GPCRs) that specifically bind and respond to the catecholamines norepinephrine (noradrenaline) and epinephrine (adrenaline), thereby mediating the physiological effects of the sympathetic nervous system. The concept of distinct adrenergic receptors was first proposed by pharmacologist Raymond Ahlquist in 1948, who classified them into alpha and beta types based on relative potencies of catecholamines.^[1] These receptors are integral membrane proteins with seven transmembrane domains, belonging to the rhodopsin-like family of GPCRs, and they transduce extracellular signals into intracellular responses via interactions with heterotrimeric G proteins.^[2] Found on the surface of various cell types throughout the body, adrenergic receptors play a central role in the "fight-or-flight" response, regulating critical functions such as cardiovascular tone, bronchodilation, and metabolic adjustments.^[3] Adrenergic receptors are broadly classified into two main categories—alpha (α) and beta (β)—with a total of nine subtypes identified across these classes: α1 (subtypes A, B, D), α2 (subtypes A, B, C), β1, β2, and β3.^[4] The α1 receptors, coupled to Gq proteins, primarily activate phospholipase C to increase intracellular calcium, leading to excitatory effects like vasoconstriction and smooth muscle contraction in blood vessels and the gastrointestinal tract.^[5] In contrast, α2 receptors, linked to Gi proteins, inhibit adenylyl cyclase and reduce cyclic AMP levels, resulting in inhibitory actions such as presynaptic inhibition of neurotransmitter release and sedation in the central nervous system.^[6] The β receptors are coupled to Gs proteins (except β3, which can couple to both Gs and Gi), stimulating adenylyl cyclase to elevate cyclic AMP and promote protein kinase A activation, which generally elicits relaxant or stimulatory responses.^[7] Specifically, β1 receptors predominate in the heart, enhancing contractility (positive inotropy), conduction velocity (positive dromotropy), and relaxation rate (positive lusitropy) to increase cardiac output.^[7] β2 receptors are abundant in the lungs and vascular smooth muscle, causing bronchodilation and vasodilation, while β3 receptors are mainly expressed in adipose tissue, facilitating lipolysis and thermogenesis.^[7] Dysregulation of these receptors is implicated in various pathologies, including hypertension, heart failure, and asthma, making them key targets for therapeutic interventions like beta-blockers and alpha-agonists.^[8]

Introduction

Definition and Discovery

Adrenergic receptors are a class of G-protein-coupled receptors (GPCRs) that specifically bind the catecholamines norepinephrine and epinephrine, thereby mediating various physiological responses to these neurotransmitters and hormones.^[9] These receptors are integral membrane proteins embedded in the plasma membrane of target cells, where they transduce extracellular signals from catecholamines into intracellular changes through interactions with G proteins.^[10] The concept of adrenergic receptors originated in the early 20th century through pharmacological investigations into the actions of adrenaline on smooth muscle. In 1905, British physiologist John Newport Langley proposed the existence of "receptive substances" on cell surfaces that selectively bind drugs like nicotine and adrenaline to elicit responses, such as muscle contraction, independent of neural mediation.^[11] This idea stemmed from experiments demonstrating that adrenaline directly affected smooth muscle tissues, suggesting intermediary molecular entities between the ligand and the cellular effector machinery.^[12] A major advance came in 1948 when pharmacologist Raymond Ahlquist classified adrenergic receptors into alpha (α) and beta (β) subtypes based on the relative potencies of sympathomimetic agents in eliciting excitatory versus inhibitory responses, laying the groundwork for modern understanding and subtype-specific pharmacology.^[1] Adrenergic receptors play a central role in the sympathetic nervous system, where they facilitate the "fight or flight" response by amplifying the effects of norepinephrine released from sympathetic nerve terminals and epinephrine from the adrenal medulla.^[8] This activation leads to rapid physiological adaptations, such as increased heart rate and redirected blood flow, essential for survival under stress.^[13]

General Physiological Roles

Adrenergic receptors serve as the primary mediators of the sympathetic nervous system's actions, binding catecholamines like norepinephrine and epinephrine released from postganglionic sympathetic nerve endings and the adrenal medulla to elicit rapid physiological adjustments.^[14] These receptors are expressed across virtually all cell types in the body, enabling widespread coordination of responses to maintain homeostasis under both normal and stressful conditions.^[15] By amplifying the low-concentration signals of circulating and locally released catecholamines, adrenergic receptors facilitate efficient signal transduction that supports the body's adaptive mechanisms, particularly during acute stress where heightened sympathetic activity is crucial.^[16] This amplification ensures that even modest increases in catecholamine levels can trigger robust effects, such as elevating heart rate and blood pressure to enhance perfusion and oxygen delivery to vital organs.^[17] In the context of survival, adrenergic receptor activation drives essential "fight-or-flight" responses, including energy mobilization through glycogenolysis and lipolysis to provide immediate fuel, as well as targeted vasodilation in skeletal muscle to support physical exertion.^[18] Concurrently, bronchodilation improves airflow and oxygenation, optimizing respiratory efficiency during demanding situations.^[19] These receptors integrate with the parasympathetic nervous system to achieve balanced autonomic control, preventing unchecked sympathetic dominance while allowing dynamic shifts in response to environmental demands.^[20]

Molecular Structure

Overall Architecture

Adrenergic receptors belong to the G protein-coupled receptor (GPCR) superfamily, characterized by a conserved overall architecture consisting of seven transmembrane α-helices (7TM) that form a barrel-like bundle embedded within the lipid bilayer of the cell membrane.^[21] This helical bundle creates a central cavity that serves as the core structural framework, with the helices connected by three intracellular loops (ICLs), three extracellular loops (ECLs), an extracellular N-terminal domain, and an intracellular C-terminal tail.^[22] The orthosteric ligand-binding pocket is located within the transmembrane region, accessible from the extracellular side, which is a hallmark feature enabling catecholamine recognition.^[23] A key structural motif conserved across adrenergic receptors and other class A GPCRs is the DRY sequence at the cytoplasmic end of transmembrane helix 3 (TM3), comprising an aspartic acid (D), arginine (R), and tyrosine (Y) triad.^[24] This motif plays a critical role in stabilizing receptor conformations and facilitating the transition between inactive and active states, with the arginine residue forming an ionic lock with residues in TM6 in the inactive form.^[25] The conservation of this sequence underscores its importance in maintaining the structural integrity and functional dynamics of the 7TM domain.^[26] Structural determination of adrenergic receptors has advanced significantly through X-ray crystallography and cryo-electron microscopy (cryo-EM). The first high-resolution crystal structure of the human β₂-adrenergic receptor (β₂AR), bound to the inverse agonist carazolol, was resolved in 2007 at 2.4 Å, revealing the precise arrangement of the 7TM helices and the ligand-binding pocket in an inactive conformation.^[27] Structures for α-adrenergic receptors have also been determined, including the crystal structure of α₂AAR in 2019 and α₁BAR in 2022, as well as cryo-EM structures of α₁AAR in 2023, confirming the shared class A GPCR fold.^[28]^[29]^[30] Post-2010 refinements for β-receptors, including cryo-EM structures of β₁AR and β₃AR complexes with G proteins and agonists (e.g., β₃AR-mirabegron-Gs at 3.2 Å in 2021, and full-length β₁AR-Gs at 3.0 Å in 2025), have provided insights into ligand-bound active states, highlighting subtle helical rearrangements while preserving the core barrel-like architecture.^[31]^[32]^[33] These studies confirm the modular nature of the GPCR fold across adrenergic subtypes.^[34]

Ligand Binding and Activation

Adrenergic receptors, as class A G protein-coupled receptors (GPCRs), feature an orthosteric binding site located within the transmembrane helical bundle, where endogenous catecholamine agonists such as epinephrine bind with high affinity, typically in the nanomolar (nM) range dissociation constant (Kd).^[35] This binding pocket is formed by residues from transmembrane helices (TMs) 3, 5, 6, and 7, along with extracellular loop 2, allowing agonists to interact via hydrogen bonds and hydrophobic contacts that stabilize the ligand in a specific orientation conducive to receptor activation.^[27] Upon agonist binding, the receptor undergoes a conformational shift from an inactive to an active state, characterized by rigid-body movements of the transmembrane helices, most notably an outward tilt of TM6 by approximately 14 Å at its intracellular end.^[36] This hallmark rearrangement opens an intracellular crevice, enabling the receptor's cytoplasmic domain to interact with heterotrimeric G proteins and initiate downstream signaling.^[37] The transition involves additional subtle adjustments, such as inward movements of TM5 and compaction of the orthosteric site, which collectively propagate the signal from the ligand-binding pocket to the G-protein coupling interface.^[38] In contrast, antagonists occupy the orthosteric site but stabilize the inactive receptor conformation by preventing the necessary helical rearrangements, thereby blocking agonist access and maintaining TM6 in its inward position without facilitating G-protein engagement.^[39] Partial agonists, such as certain synthetic ligands, bind similarly but induce only intermediate conformational states, resulting in partial TM6 displacement and suboptimal G-protein activation compared to full agonists like epinephrine.^[40] These efficacy differences arise from the ligands' ability to stabilize distinct equilibrium populations of receptor conformations, with partial agonists favoring less productive intermediates.^[41]

Classification and Subtypes

α1-Adrenergic Receptors

The α1-adrenergic receptors (α1-ARs) constitute a subtype family within the broader class of adrenergic receptors, consisting of three distinct subtypes: α1A (encoded by ADRA1A), α1B (encoded by ADRA1B), and α1D (encoded by ADRA1D).^[42] These subtypes are all members of the G protein-coupled receptor superfamily and share high sequence homology, particularly in their transmembrane domains, which facilitate ligand binding to catecholamines such as norepinephrine and epinephrine.^[43] The genes encoding these receptors are located on different chromosomes in humans: ADRA1A on chromosome 8p21.2, ADRA1B on 5q33.3, and ADRA1D on 20p13.^[44]^[45]^[46] All α1-AR subtypes couple primarily to the Gq protein, which activates phospholipase C (PLC), leading to the hydrolysis of phosphatidylinositol 4,5-bisphosphate into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG).^[47] This signaling cascade mobilizes intracellular calcium and activates protein kinase C, enabling diverse cellular responses.^[48] Subtype-specific variations in signaling efficiency and tissue expression contribute to their functional specialization, with α1A often predominant in certain vascular beds.^[49] α1-ARs are predominantly distributed in vascular smooth muscle, where they mediate contraction; the liver, where they influence metabolic processes like glycogenolysis; and the central nervous system (CNS), where they modulate neuronal excitability and synaptic plasticity.^[2]^[42] In the CNS, α1-ARs are expressed in regions such as the cortex and hippocampus, contributing to arousal and cognitive functions.^[6] Hepatic expression is notable in hepatocytes and supports sympathetic regulation of glucose homeostasis.^[50] The primary functions of α1-ARs include vasoconstriction and contraction of smooth muscle, which are critical for maintaining vascular tone and blood pressure.^[51] Specifically, the α1A subtype plays a key role in hypertension by mediating vasoconstriction in resistance arteries, where its activation by catecholamines increases peripheral resistance.^[52] This subtype's expression in arterial smooth muscle underscores its importance in both physiological blood pressure regulation and pathological conditions like essential hypertension.^[49]

α2-Adrenergic Receptors

The α2-adrenergic receptors comprise three subtypes, α2A, α2B, and α2C, which belong to the family of G protein-coupled receptors.^[53] These subtypes couple to Gi/o proteins, leading to the inhibition of adenylyl cyclase and a subsequent reduction in intracellular cyclic AMP (cAMP) levels.^[54] This signaling mechanism allows α2 receptors to exert inhibitory effects on various cellular processes, distinguishing them from excitatory α1 and β subtypes. α2-adrenergic receptors are prominently distributed on presynaptic neurons, where they function as autoreceptors, as well as in the pancreas and vascular endothelium.^[9] In the pancreas, particularly on β-cells, they modulate insulin secretion, while in vascular endothelium, they contribute to the regulation of local vascular tone.^[55]^[56] The subtypes exhibit tissue-specific expression: α2A is abundant in the central nervous system (CNS), α2B in peripheral vascular tissues, and α2C in additional select locations. A primary function of presynaptic α2 receptors is to provide negative feedback inhibition of norepinephrine release from adrenergic neurons, thereby limiting sympathetic outflow.^[53] In the CNS, the α2A subtype plays a key role in mediating sedation and analgesia through activation in regions such as the locus coeruleus.^[57] Additionally, the α2B subtype contributes to vasoconstrictor responses in vascular smooth muscle, including those involved in cold-induced vasoconstriction in the skin to conserve heat.^[58]

β1-Adrenergic Receptors

The β1-adrenergic receptor (β1-AR) is a single subtype of the β-adrenergic receptor family, belonging to the G protein-coupled receptor superfamily. It is primarily coupled to the stimulatory G protein (Gs), which upon activation by agonists such as norepinephrine and epinephrine, stimulates adenylyl cyclase to increase intracellular cyclic AMP (cAMP) levels. This, in turn, activates protein kinase A (PKA), initiating downstream signaling cascades that mediate various physiological responses.^[17] β1-ARs are predominantly expressed in the heart, where they constitute approximately 80% of all cardiac β-adrenergic receptors, and in the kidneys, particularly in juxtaglomerular cells. In the heart, they are localized to the sinoatrial node, atrioventricular node, and both atrial and ventricular cardiomyocytes, enabling precise regulation of cardiac activity.^[59]^[17]^[20] The primary functions of β1-ARs in the heart involve positive chronotropy (increased heart rate) and inotropy (increased contractility), which enhance cardiac output during sympathetic activation. This is achieved through PKA-mediated phosphorylation of key targets, including L-type calcium channels, which increases calcium influx and thereby boosts myocardial contractility.^[60]^[61] The gene encoding β1-AR, ADRB1, is located on chromosome 10q25.3. Common polymorphisms in ADRB1, such as Arg389Gly, influence receptor function and clinical outcomes; for instance, the Arg389 variant enhances Gs coupling and is associated with altered responses in heart failure patients.^[62]^[63]^[64]

β2-Adrenergic Receptors

The β₂-adrenergic receptor (β₂-AR) is a key subtype within the β-adrenergic receptor family, primarily coupling to the stimulatory G protein (Gₛ) to activate adenylyl cyclase and increase intracellular cyclic AMP (cAMP) levels, thereby initiating protein kinase A (PKA)-dependent signaling cascades.^[65] However, β₂-AR also engages β-arrestin pathways, enabling biased signaling where certain ligands preferentially activate either Gₛ or β-arrestin-mediated effects, such as MAPK activation, independent of G protein involvement.^[65] This dual signaling capacity distinguishes β₂-AR from other subtypes and allows for nuanced physiological responses.^[66] β₂-ARs are predominantly expressed in smooth muscle tissues, including the bronchi and vascular walls, where they mediate relaxation; they are also found in skeletal muscle and hepatocytes in the liver.^[67] In airway smooth muscle, β₂-AR activation promotes bronchodilation by relaxing bronchial smooth muscle cells through elevated cAMP and PKA activity.^[68] Similarly, in vascular smooth muscle, particularly in skeletal muscle beds, stimulation induces vasodilation, enhancing blood flow during sympathetic activation.^[67] In skeletal muscle, β₂-ARs contribute to metabolic regulation, including increased glucose uptake and contractility support. A critical metabolic role of hepatic β₂-ARs involves the promotion of glycogenolysis, where receptor activation elevates cAMP, leading to PKA phosphorylation and activation of enzymes such as phosphorylase kinase, which breaks down glycogen to glucose-1-phosphate for energy mobilization.^[69] Post-2015 studies on biased agonism have highlighted how ligands like β-arrestin-biased pepducins can selectively trigger anti-apoptotic and contractile effects in cardiomyocytes via β-arrestin pathways, while Gₛ-biased agonists emphasize relaxation and metabolic shifts, offering insights into tailored therapeutic strategies.^[66] Further research has shown that G protein-coupled receptor kinases (GRKs) orchestrate this bias by modulating β-arrestin recruitment, influencing downstream gene expression and cellular outcomes.^[70]

β3-Adrenergic Receptors

The β3-adrenergic receptor (β3-AR) is the third subtype in the β-adrenergic receptor family, classified as a class A G protein-coupled receptor (GPCR) that primarily couples to the stimulatory G protein (Gs). Unlike β1- and β2-ARs, the β3-AR exhibits atypical signaling characteristics, including reduced susceptibility to desensitization due to the absence of key phosphorylation sites for protein kinase A (PKA) and β-adrenergic receptor kinase (βARK), allowing for sustained activation. This leads to Gs-mediated elevation of cyclic AMP (cAMP) levels, which activates PKA to phosphorylate hormone-sensitive lipase (HSL), promoting lipolysis, although some studies indicate potential cAMP-independent pathways enhancing HSL activity in adipose tissue.^[71]^[72]^[73] β3-ARs are predominantly expressed in metabolic tissues, with high levels in white and brown adipose tissue, where they regulate energy homeostasis, as well as in the urinary bladder and gallbladder, contributing to smooth muscle relaxation. In humans, expression is lower compared to rodents, but it remains functionally significant in adipocytes and detrusor muscle. The receptor shows lower affinity for endogenous catecholamines like norepinephrine compared to β1- and β2-ARs, preferring epinephrine and requiring higher concentrations for activation, which influences its physiological selectivity.^[71]^[74]^[2] In white adipose tissue, β3-AR activation drives lipolysis by stimulating HSL to hydrolyze triglycerides into free fatty acids and glycerol, providing energy substrates during fasting or stress. In brown adipose tissue, it induces thermogenesis through PKA-mediated phosphorylation and activation of uncoupling protein 1 (UCP1) in mitochondria, dissipating the proton gradient to generate heat rather than ATP, a process central to non-shivering thermogenesis. This UCP1-dependent mechanism has been targeted for obesity treatment, as β3-AR agonists enhance energy expenditure and reduce fat mass in preclinical models. Additionally, in the urinary bladder, β3-ARs mediate detrusor muscle relaxation; the selective agonist mirabegron activates these receptors to alleviate overactive bladder symptoms by increasing bladder capacity without significant cardiac effects.^[71]^[75]^[76]^[77]

Signaling Mechanisms

G-Protein Coupling Pathways

Adrenergic receptors, as members of the G protein-coupled receptor (GPCR) superfamily, transduce signals from catecholamines such as epinephrine and norepinephrine by coupling to specific heterotrimeric G proteins, which in turn modulate effector enzymes and ion channels to initiate intracellular signaling cascades.^[78] The specificity of G protein coupling varies among the receptor subtypes, determining the primary second messenger systems activated and thereby shaping the physiological response. This subtype-specific coupling is a key feature that allows adrenergic receptors to elicit diverse effects across tissues.^[79] The α1-adrenergic receptors (α1-ARs) primarily couple to Gq/11 proteins upon agonist binding, leading to the activation of phospholipase C-β (PLC-β).^[79] Activated PLC-β hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 subsequently binds to IP3 receptors on the endoplasmic reticulum, triggering the release of Ca²⁺ into the cytosol, while DAG recruits and activates protein kinase C (PKC), which phosphorylates downstream targets.^[79] This pathway is conserved across α1A, α1B, and α1D subtypes, though subtle differences in efficiency may exist.^[80] In contrast, α2-adrenergic receptors (α2-ARs) couple predominantly to Gi/o proteins, inhibiting adenylyl cyclase (AC) activity and thereby reducing cyclic adenosine monophosphate (cAMP) levels.^[81] This inhibition decreases the activity of cAMP-dependent protein kinase A (PKA), attenuating processes reliant on cAMP signaling. Additionally, the Gβγ subunits released from Gi/o can directly modulate ion channels, such as inhibiting voltage-gated Ca²⁺ channels or activating G protein-gated inwardly rectifying K⁺ (GIRK) channels.^[82] Although α2-ARs can exhibit weak coupling to Gs in certain contexts, Gi/o remains the dominant pathway across α2A, α2B, and α2C subtypes.^[83] The β-adrenergic receptors (β-ARs) couple to Gs proteins, stimulating adenylyl cyclase to increase cAMP production from ATP.^[84] The reaction catalyzed by AC can be represented as:

\text{ATP} \xrightarrow{\text{AC}} \text{cAMP} + \text{PP}_\text{i}

where the production rate of cAMP is influenced by the concentration of ATP substrate and the activity level of AC, modulated by Gsα-GTP.^[85] Elevated cAMP then activates PKA, which phosphorylates various substrates to amplify the signal. This pathway is characteristic of β1-AR and β2-AR, with β1-AR showing particularly robust coupling in cardiac tissues.^[31] Notably, the β3-AR exhibits atypical coupling, displaying a bias toward Gi in certain tissues alongside its primary Gs interaction, which can lead to context-dependent inhibition of AC.^[86] Subtype-specific G protein coupling thus dictates the effector pathways, enabling precise regulation of cellular responses; for instance, the Gi bias of β3-AR in adipocytes contrasts with the strong Gs preference of β1-AR in cardiomyocytes.^[86]

Downstream Effects

Upon activation of Gs-coupled adrenergic receptors, such as β subtypes, the resulting increase in intracellular cAMP activates protein kinase A (PKA), which phosphorylates a variety of downstream targets to elicit cellular responses.^[87] PKA-mediated phosphorylation of ion channels, including the L-type calcium channel Cav1.2 at serine 1928, enhances channel activity and calcium influx in excitable cells.^[88] Additionally, PKA phosphorylates the transcription factor CREB at serine 133, promoting its binding to cAMP response elements and thereby regulating gene expression involved in cell survival and differentiation.^[89] A critical downstream adaptation is receptor desensitization, primarily mediated by G protein-coupled receptor kinases (GRKs), which phosphorylate activated adrenergic receptors to uncouple them from G proteins. In β2-adrenergic receptors, GRK2 and GRK3 preferentially phosphorylate the receptor's C-terminal tail and third intracellular loop upon agonist stimulation, initiating homologous desensitization that is specific to the stimulated receptor subtype.^[90] This phosphorylation creates a binding site for β-arrestins, which sterically hinder further G protein interaction and promote receptor internalization via clathrin-coated pits, thereby terminating signaling and facilitating receptor recycling or degradation.^[91] Beyond desensitization, β-arrestin recruitment enables non-canonical signaling pathways, including the activation of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) cascades, which influence cell proliferation and survival. In β1- and β2-adrenergic receptors, β-arrestin 2 scaffolds ERK1/2, leading to its phosphorylation and nuclear translocation independent of G protein pathways.^[92] This β-arrestin-dependent ERK signaling exemplifies biased agonism, where certain ligands preferentially stabilize receptor conformations that favor arrestin over G protein effectors, allowing selective modulation of downstream outcomes.^[65] Recent studies have identified allosteric modulators that fine-tune this bias in adrenergic receptors. For instance, compound-6 acts as a positive allosteric modulator of the β2-adrenergic receptor, enhancing β-arrestin-biased signaling when combined with certain antagonists like carvedilol, potentially offering therapeutic advantages by decoupling desensitization from beneficial effects.^[93] Similarly, a negative allosteric modulator has been shown to promote Gs-biased signaling at β2-adrenergic receptors, reducing β-arrestin recruitment and sustaining cAMP production.^[94] These post-2020 findings highlight the potential for allosteric ligands to influence long-term adaptations like receptor trafficking and pathway selectivity.

Physiological Functions

Cardiovascular Regulation

Adrenergic receptors play a central role in cardiovascular homeostasis by modulating heart rate, contractility, and vascular tone in response to sympathetic nervous system activation. The β1-adrenergic receptors, predominantly expressed in the heart, particularly in the sinoatrial node, mediate chronotropic effects by increasing heart rate (tachycardia) through enhanced cyclic AMP production and subsequent activation of pacemaker currents.^[20] This response is crucial during stress or exercise to elevate cardiac output. Concurrently, α1-adrenergic receptors in arterial smooth muscle cells induce vasoconstriction by activating phospholipase C, leading to increased intracellular calcium and contraction, which helps maintain peripheral resistance and blood pressure.^[95] The integration of multiple adrenergic subtypes ensures fine-tuned blood pressure maintenance. For instance, presynaptic α2-adrenergic receptors on sympathetic nerve terminals provide negative feedback by inhibiting norepinephrine release, thereby modulating baroreflex sensitivity and preventing excessive sympathetic outflow during pressure changes.^[96] This mechanism contributes to the baroreflex's role in stabilizing arterial pressure by balancing sympathetic and parasympathetic inputs. In pathological states like heart failure, chronic activation of β1-adrenergic receptors promotes adverse cardiac remodeling, including hypertrophy, fibrosis, and myocyte apoptosis, driven by sustained signaling through protein kinase A and calcium/calmodulin-dependent kinase II pathways.^[97] Sympathetic activation via adrenergic receptors also facilitates overall circulatory adjustments, increasing cardiac output through β1-mediated enhancements in heart rate and contractility while promoting blood flow redistribution. α1-mediated vasoconstriction in non-essential vascular beds, such as skin and splanchnic circulation, redirects blood to vital organs like the heart and brain, optimizing oxygen delivery during acute demands.^[98] This coordinated response underscores the receptors' essential function in both basal regulation and adaptive stress responses.

Respiratory and Metabolic Roles

Adrenergic receptors significantly influence respiratory physiology by modulating airway tone and smooth muscle contractility. The β₂-adrenergic receptors, abundant in bronchial smooth muscle, promote bronchodilation through activation of adenylate cyclase, which elevates intracellular cyclic AMP levels and leads to relaxation of airway smooth muscle cells. This mechanism is central to the therapeutic efficacy of β₂-agonists like salbutamol in managing asthma, where they counteract bronchoconstriction to improve ventilation and reduce symptoms during acute exacerbations.^[99] In opposition, α₁-adrenergic receptors mediate bronchial constriction by coupling to Gq proteins, triggering phospholipase C activation, calcium release, and subsequent contraction of airway smooth muscle. This constrictive effect can worsen airway resistance in asthmatics, as demonstrated by studies showing alpha-adrenergic agonists induce significant narrowing in isolated human airways and in vivo models of bronchial hyperresponsiveness.^[100] Beyond respiration, adrenergic receptors orchestrate key metabolic processes, particularly in energy mobilization and substrate utilization. β₃-adrenergic receptors, primarily expressed in adipocytes, drive lipolysis by stimulating hormone-sensitive lipase via Gs-protein-mediated cAMP increase, resulting in the hydrolysis of triglycerides into free fatty acids and glycerol for systemic energy supply. This fat mobilization is crucial for thermogenesis in brown adipose tissue and overall lipid homeostasis, with disruptions linked to obesity and metabolic disorders in human and rodent models.^[101] Complementing this, β₂-adrenergic receptors facilitate glycogenolysis in the liver and skeletal muscle by similarly elevating cAMP, which activates protein kinase A and phosphorylates glycogen phosphorylase to break down glycogen into glucose-1-phosphate. In the liver, this supports gluconeogenesis and glucose release into circulation, while in muscle, it provides rapid local ATP production during demand.^[102]^[50] A pivotal integration of these respiratory and metabolic functions occurs during exercise, where sympathetic activation of β₂-adrenergic receptors enhances oxygen delivery through bronchodilation and peripheral vasodilation, while simultaneously boosting fuel availability via accelerated glycogenolysis and lipolysis. This coordinated response increases pulmonary ventilation, cardiac output, and substrate flux to working muscles, enabling sustained aerobic performance and preventing fatigue, as evidenced in studies of β₂ polymorphisms affecting exercise capacity.^[103] Additionally, β₂-adrenergic receptors contribute to uterine relaxation during labor by inducing myometrial smooth muscle quiescence through cAMP-dependent inhibition of contractility, a process exploited in tocolytic therapy to inhibit preterm delivery. Protein levels of these receptors decrease at term labor, potentially facilitating the transition to active contractions.^[104]^[105]

Neurological and Other Functions

Adrenergic receptors play crucial roles in central nervous system functions, particularly in regulating arousal and sedation through α₂-adrenergic receptors in the locus coeruleus (LC). Activation of postsynaptic α₂ receptors on LC neurons leads to hyperpolarization, inhibiting neuronal firing and reducing norepinephrine release, which promotes sedation and decreases arousal states.^[106] This mechanism underlies the sedative effects of α₂ agonists like clonidine, which mimic endogenous norepinephrine to dampen LC activity.^[107] In the hippocampus, β₁- and β₂-adrenergic receptors modulate synaptic plasticity and memory formation. Norepinephrine acting on these β receptors enhances long-term potentiation (LTP), a cellular correlate of learning, by facilitating cAMP signaling and gene expression necessary for memory consolidation.^[108] β₂ receptors, in particular, on astrocytes contribute to contextual fear memory by promoting gliotransmitter release that supports neuronal plasticity.^[109] Both subtypes are differentially distributed across hippocampal subregions, with β₁ more prominent in CA3 for spatial memory processes.^[110] Adrenergic signaling also influences attention and pain modulation. α₂ receptors in the prefrontal cortex strengthen noradrenergic transmission, improving attentional control and executive function by reducing distractor interference.^[111] In pain pathways, LC-derived norepinephrine via α₂ and β receptors inhibits nociceptive transmission in the spinal cord and brainstem, providing descending analgesia.^[112] This role extends to attention-deficit/hyperactivity disorder (ADHD), where α₂ agonists like guanfacine enhance prefrontal α₂A receptor activity to ameliorate inattention and impulsivity symptoms through improved working memory and behavioral inhibition.^[111] Beyond the central nervous system, adrenergic receptors mediate peripheral functions such as pupil dilation and bladder control. α₁-adrenergic receptors, primarily the α₁A subtype, on the iris dilator muscle induce contraction, resulting in mydriasis (pupil dilation) in response to sympathetic activation.^[113] In the urinary bladder, β₃-adrenergic receptors on detrusor smooth muscle promote relaxation, increasing bladder capacity during the storage phase of micturition without affecting contraction.^[114] Additionally, sympathetic adrenergic activation via α₂ and β receptors inhibits gastrointestinal motility by suppressing enteric neuron activity and smooth muscle contraction, contributing to the "fight-or-flight" reduction in digestive processes.^[115]

Pharmacology and Therapeutics

Agonists and Antagonists

Adrenergic receptor agonists are compounds that bind to and activate these G protein-coupled receptors, mimicking the effects of endogenous catecholamines such as norepinephrine and epinephrine. Non-selective agonists like epinephrine activate both α- and β-adrenergic receptors, leading to widespread physiological responses across multiple subtypes.^[4] In contrast, β-selective agonists such as isoproterenol primarily target β1- and β2-adrenergic receptors, providing more focused stimulation of β-mediated pathways.^[4] For greater specificity, β2-selective agonists like salbutamol exhibit high affinity for the β2 subtype while having minimal activity at β1 or α receptors, which enhances their utility in targeted applications.^[99] Antagonists, or blockers, inhibit adrenergic receptor activation by competing with agonists for binding sites, thereby reducing sympathetic signaling. α-Adrenergic antagonists are classified by subtype selectivity; for instance, prazosin is a selective α1-blocker that potently inhibits α1 receptors with little effect on α2 subtypes.^[116] Yohimbine, on the other hand, serves as a selective α2-antagonist, demonstrating high affinity for α2 receptors and lower binding to α1.^[117] β-Adrenergic antagonists similarly vary in selectivity: propranolol acts as a non-selective β-blocker, antagonizing both β1 and β2 receptors equally.^[118] Atenolol, by comparison, is β1-selective, preferentially blocking β1 receptors in cardiac tissue with reduced impact on β2-mediated functions.^[118] Selectivity profiles are crucial in adrenergic pharmacology, as they determine the therapeutic window and side effect profile of these agents; for example, β2-selective agonists like salbutamol minimize cardiac stimulation compared to non-selective counterparts.^[99] Beyond competitive antagonists, some adrenergic blockers function as inverse agonists, which not only prevent agonist binding but also actively stabilize the receptor in its inactive conformation, reducing constitutive (ligand-independent) activity.^[119] Propranolol exemplifies this at β-adrenergic receptors, where it suppresses basal signaling more effectively than neutral antagonists.^[119] Similarly, prazosin exhibits inverse agonism at α1-adrenergic receptors, further dampening spontaneous receptor activation.^[120]

Clinical Applications

Adrenergic receptor modulators play a central role in managing various cardiovascular and respiratory conditions through targeted antagonism or agonism. β1-selective blockers, such as metoprolol, are widely used to treat hypertension and chronic stable angina by reducing heart rate and myocardial oxygen demand, thereby alleviating chest pain and lowering blood pressure.^[121] These agents demonstrate efficacy in reducing the frequency and severity of anginal episodes, with metoprolol specifically approved for long-term management of these conditions.^[122] Similarly, α1-antagonists like tamsulosin are employed in benign prostatic hyperplasia (BPH) to relax smooth muscle in the prostate and bladder neck, improving lower urinary tract symptoms such as urgency and weak stream. Clinical trials have shown tamsulosin to be effective in patients with mild to severe BPH symptoms, including those with comorbidities like diabetes, with significant improvements in urinary flow rates observed within weeks of initiation.^[123] Long-term use maintains efficacy, with over 80% of patients showing sustained symptom relief after six years.^[124] Agonists targeting specific adrenergic subtypes also offer therapeutic benefits in acute and chronic settings. For instance, the β2-agonist albuterol is a cornerstone in asthma management, acting as a short-acting bronchodilator to relieve bronchospasm and improve airflow during exacerbations.^[125] Inhaled albuterol rapidly reduces symptoms in patients with asthma and chronic obstructive pulmonary disease by stimulating β2 receptors on airway smooth muscle.^[99] For hypertension, the α2-agonist clonidine lowers blood pressure primarily through central sympatholytic effects, reducing sympathetic outflow from the brainstem.^[126] Clonidine is particularly useful in patients with resistant hypertension, providing effective control when combined with other agents.^[53] A critical application involves epinephrine, a non-selective α- and β-agonist, which is the first-line treatment for anaphylaxis; it reverses life-threatening symptoms like hypotension and airway edema by vasoconstriction via α-receptors and bronchodilation via β-receptors.^[127] While these modulators are efficacious, side effects must be considered in clinical practice. α1-blockers, including tamsulosin, can induce reflex tachycardia due to vasodilation and subsequent baroreceptor-mediated sympathetic activation, potentially leading to palpitations or orthostatic hypotension.^[116] This compensatory tachycardia is more pronounced with non-selective agents but remains a notable concern even with uroselective ones like tamsulosin.^[128] In the context of β3-adrenergic receptors, the agonist mirabegron represents a novel therapeutic option for overactive bladder (OAB), approved by the FDA in 2012 for reducing urgency, frequency, and incontinence episodes. Mirabegron activates β3 receptors in the bladder detrusor muscle to promote relaxation during the storage phase, demonstrating significant improvements in patient-reported outcomes and health-related quality of life compared to placebo.^[129] Clinical studies confirm its efficacy, with reductions in micturition frequency and urgency incontinence episodes observed at doses of 50 mg daily.^[77]

Genetic and Research Aspects

Genetic Variations and Polymorphisms

Adrenergic receptors are encoded by genes susceptible to single nucleotide polymorphisms (SNPs) and other variations that can modify receptor density, ligand binding affinity, or downstream signaling efficiency, thereby influencing physiological responses and disease risk.^[130] These genetic alterations often contribute to inter-individual differences in adrenergic signaling, particularly in conditions involving sympathetic nervous system dysregulation such as cardiovascular and respiratory disorders.^[131] A prominent example is the Ser49Gly polymorphism in the ADRB1 gene, which encodes the β1-adrenergic receptor. The Gly49 variant is associated with reduced receptor density on the cell surface, leading to diminished cAMP production and a blunted response to agonists compared to the wild-type Ser49 allele.^[132] In patients with heart failure with reduced ejection fraction (HFrEF), this polymorphism has been linked to improved left ventricular ejection fraction recovery and better prognosis, particularly under β-blocker therapy.^[131] Similarly, the α2C-adrenergic receptor features a deletion variant (Del322-325) in the ADRA2C gene that impairs receptor function by reducing autoinhibitory control over norepinephrine release. This variant, when homozygous, increases the risk of heart failure development approximately fivefold in African American populations, highlighting population-specific genetic contributions to cardiovascular disease susceptibility.^[133] In the β2-adrenergic receptor, the Arg16Gly SNP in ADRB2 alters ligand affinity and receptor desensitization, with the Gly16 allele conferring greater sensitivity to β-agonists but increased risk of tachyphylaxis upon chronic exposure. This polymorphism significantly impacts therapeutic responses in asthma, where Gly16 homozygotes exhibit reduced bronchodilation efficacy to short-acting β-agonists like albuterol, influencing personalized treatment strategies.^[134] Genome-wide association studies conducted after 2010 have implicated the ADRA2A gene, encoding the α2A-adrenergic receptor, in attention-deficit/hyperactivity disorder (ADHD) susceptibility, with specific polymorphisms such as rs1800544 associated with altered prefrontal cortex function and symptom severity in affected individuals.^[135]

Recent Advances and Future Directions

Recent advances in structural biology have significantly enhanced understanding of adrenergic receptor mechanisms, particularly through cryo-electron microscopy (cryo-EM) studies. In 2022, the cryo-EM structure of the α2A-adrenergic receptor (α2AAR) in complex with G proteins and biased agonists revealed novel allosteric sites that modulate ligand binding and signaling selectivity, enabling the discovery of nonopioid analgesics targeting pain pathways without central nervous system side effects.^[136] These structures highlight how allosteric modulation can fine-tune receptor activation, addressing previous gaps in visualizing inactive and intermediate states.^[54] Progress in biased agonism has opened avenues for more targeted therapies, especially in cardiovascular diseases. Selective β-arrestin-biased agonists, such as derivatives inspired by carvedilol, activate β1- and β2-adrenergic receptors to promote cardioprotective signaling in heart failure while avoiding G protein-mediated tachycardia.^[137] For instance, carvedilol's bias toward β-arrestin pathways enhances extracellular signal-regulated kinase activation via epidermal growth factor receptor transactivation, improving cardiac remodeling without increasing heart rate.^[138] This approach mitigates the limitations of traditional β-blockers by decoupling beneficial anti-apoptotic effects from adverse chronotropic responses.^[139] Emerging research tools like optogenetics and CRISPR/Cas9 have elucidated receptor trafficking dynamics and therapeutic potential in neurodegenerative disorders. Chemogenetic modulation of noradrenergic locus coeruleus neurons, which express α2-adrenergic autoreceptors, has demonstrated regulation of dopamine neuron survival in Parkinson's disease models by controlling norepinephrine release and receptor internalization.^[140] In Parkinson's contexts, α2 modulation via these techniques shows promise for reducing neuroinflammation and enhancing levodopa efficacy without exacerbating motor symptoms.^[141] Adrenergic receptors exhibit strong evolutionary conservation across species, underscoring their fundamental role in stress responses from invertebrates to mammals. Studies in mollusks like the Pacific oyster reveal duplicated α- and β-subtypes with shared motifs for ligand binding, suggesting ancient origins predating vertebrate genome duplications.^[142] This conservation extends to an emerging role for β2-adrenergic receptors in cancer, where chronic sympathetic activation promotes tumor growth through cyclic AMP-mediated metabolic reprogramming and immune suppression in the microenvironment.^[143] For example, β2 signaling enhances prostate cancer progression by upregulating Sonic hedgehog pathways, highlighting potential for antagonists in oncology.^[144] Looking ahead, pharmacogenomics promises personalized interventions tailored to adrenergic receptor variants. Genetic testing for polymorphisms in ADRB1 and ADRB2 can predict β-blocker responses in hypertension and heart failure, guiding dose adjustments to optimize efficacy and minimize adverse events.^[145] In obesity management, β3-adrenergic agonists like mirabegron and novel compounds such as ATR-127 are advancing in clinical trials as of 2024, activating brown adipose thermogenesis to induce weight loss without cardiovascular risks associated with earlier pan-β agonists.^[146] As of mid-2025, Phase 2 trials for ATR-258, a β3-selective agent, are planned to evaluate its effects on body composition and metabolic outcomes.^[147]

References

[1]
Adrenergic receptors: structure and function - PubMed - NIH
Adrenergic receptors are cell surface glycoproteins that recognize and selectively bind the catecholamines, norepinephrine and epinephrine.
[2]
Adrenoceptors | Introduction
Adrenoceptors (AR) are a group of nine 7-transmembrane receptors comprising 3 main types, α1, α2 and β, each with 3 subtypes that mediate the central and ...
[3]
The β3-Adrenergic Receptor: Structure, Physiopathology of Disease ...
Adrenergic receptors also known as adrenoceptors constitute a rhodopsin class A type of GPCRs that stimulate the sympathetic nervous system (SNS) [3]. Agonists ...
[4]
Adrenergic Drugs - StatPearls - NCBI Bookshelf
Adrenergic receptors, otherwise known as adreno-receptors, are classified as either alpha or beta receptors. Those two classes are further subdivided into ...
[5]
Role of α- and β-adrenergic signaling in phenotypic targeting
Jul 20, 2021 · α- adrenoceptors mediate smooth muscle contraction and vasoconstriction, while β-adrenoceptors mediate vasodilation, smooth muscle relaxation, ...
[6]
α1-Adrenergic Receptors in Neurotransmission, Synaptic ... - Frontiers
There exists a total of three AR families and nine subtypes (α1A, α1B, α1D, α2A, α2B, α2C, β1, β2, and β3) that display similar binding affinities but evoke ...
[7]
α- and β-Adrenergic Receptors - Basic Neurochemistry - NCBI - NIH
β 1 -Adrenergic receptors predominate in the heart and in the cerebral cortex, whereas β 2 -adrenergic receptors predominate in the lung and cerebellum.
[8]
Adrenergic receptors and cardiovascular effects of catecholamines
Mar 18, 2020 · This review details the regulation of cardiac and vascular function by adrenergic receptors.
[9]
Physiology, Catecholamines - StatPearls - NCBI Bookshelf - NIH
Dec 11, 2024 · Epinephrine and norepinephrine influence cells by binding to adrenergic receptors, a class of G protein-coupled receptors (GPCRs). These ...Introduction · Function · Mechanism · Related Testing
[10]
Adrenergic Receptor - an overview | ScienceDirect Topics
Adrenergic receptors (ARs) are G-protein-coupled receptors that mediate physiological processes in response to catecholamines, and are membrane-bound proteins.
[11]
“Receptive Substances”: John Newport Langley (1852–1925) and ...
In December 1905, in his classic paper on “receptive substances”, Langley critically reviewed the evidence that had so far been provided on the direct action ...
[12]
The concept of transmitter receptors: 100 years on - PubMed
It is nearly one hundred years since John Langley of Cambridge developed the idea of the 'receptive substance' or 'receptors' as we now call them.
[13]
Physiology, Stress Reaction - StatPearls - NCBI Bookshelf
May 7, 2024 · Activating the sympathetic nervous system in this manner triggers an acute stress response called the fight-or-flight response. This response ...Introduction · Cellular Level · Organ Systems Involved · Mechanism
[14]
Pharmacology and Physiology of Human Adrenergic Receptor ...
Apr 1, 2003 · Adrenergic receptors are expressed on virtually every cell type in the body and are the receptors for epinephrine and norepinephrine within ...
[15]
Pharmacology and physiology of human adrenergic receptor ...
They serve critical roles in maintaining homeostasis in normal physiologic settings as well as pathologic states.
[16]
Adrenergic Receptor Function - an overview | ScienceDirect Topics
β-Adrenergic receptors (βARs) control key physiological functions by transducing signals encoded in catecholamine hormones and neurotransmitters to activate ...
[17]
Beta 1 Receptors - StatPearls - NCBI Bookshelf - NIH
Beta-1 receptors, along with beta-2, alpha-1, and alpha-2 receptors, are adrenergic receptors primarily responsible for signaling in the sympathetic nervous ...Bookshelf · Introduction · Clinical Significance
[18]
Role of adrenergic receptor signalling in neuroimmune communication
This review discusses the expression of different adrenergic receptors in various immune cells, signalling, and how it modulates immune cell function and ...
[19]
Neuroanatomy, Sympathetic Nervous System - StatPearls - NCBI - NIH
The functions of the sympathetic nervous system are expansive and involve many organ systems and various types of adrenergic receptors. The effects in which ...Introduction · Structure and Function · Physiologic Variants · Surgical Considerations
[20]
Autonomic and endocrine control of cardiovascular function - PMC
The stimulation of the sympathetic nervous system causes pupil dilatation, bronchiole dilatation, blood vessel constriction, sweat secretion, inhibits ...
[21]
Structural insights into G-protein-coupled receptor activation - PMC
GPCRs share a common architecture within the membrane consisting of seven transmembrane (TM)-spanning helices, with an extracellular amino terminus and a ...
[22]
G protein-coupled receptors (GPCRs): advances in structures ...
Apr 10, 2024 · GPCRs are the largest superfamily of cell surface membrane receptors and are encoded by approximately 1000 genes, sharing conserved seven-transmembrane (7TM) ...
[23]
High-Resolution Crystal Structure of an Engineered Human β 2
Nov 23, 2007 · We report the crystal structure of a human β 2 -adrenergic receptor–T4 lysozyme fusion protein bound to the partial inverse agonist carazolol at 2.4 angstrom ...Missing: Kobilka | Show results with:Kobilka
[24]
Adrenergic Receptor Involves Disruption of an Ionic Lock between ...
Figure 1 A, helical net representation of the β2-adrenergic receptor. The highly conserved DRY motif is located at the cytoplasmic side of TM3. The conserved ...
[25]
The Arginine of the DRY Motif in Transmembrane Segment III ... - NIH
The ArgIII:26 micro-switch stabilizes both active and inactive receptor conformations but is not directly involved in receptor signaling.
[26]
Divergent roles of DRY and NPxxY motifs in selective activation of ...
The highly conserved DRY motif, located at the cytoplasmic end of the TM3 is crucial in orchestrating the switch between inactive and ligand dependent ...
[27]
Crystal structure of the human β2 adrenergic G-protein ... - Nature
Oct 21, 2007 · Here we report a structure of the human β 2 adrenoceptor (β 2 AR), which was crystallized in a lipid environment when bound to an inverse agonist.Missing: Kobilka | Show results with:Kobilka
[28]
Structures of β1-adrenergic receptor in complex with Gs and ligands ...
Jul 14, 2022 · We report the cryo-EM structures of β 1 -adrenergic receptor (β 1 -AR) in complex with Gs (Gα s Gβ 1 Gγ 2 ) and a partial agonist or a very weak
[29]
Cryo-EM structure of the β3-adrenergic receptor reveals ... - Cell Press
Jul 26, 2021 · Cryo-EM β 3 adrenergic receptor structure complexes with mirabegron and Gα s. Mirabegron adopts an elongated shape and fits vertically within the pocket.
[30]
G Protein-Coupled Receptors: A Century of Research and Discovery
Jun 20, 2024 · Langley, who coined the term receptive substance in 1905 while studying the contractions of muscle cells stimulated by nicotine. He ...
[31]
High-affinity binding of agonists to beta-adrenergic receptors ... - PNAS
much higher than the Kd values (38 nM for isoproterenol, 210. nM for epinephrine) for inhibition of binding to receptors in membrane preparations. These ...
[32]
Common activation mechanism of class A GPCRs - eLife
Dec 19, 2019 · Receptor activation is triggered by ligand binding and is characterised by movements of different transmembrane helices. How does ligand-induced ...
[33]
Agonist-induced conformational changes in the G-protein-coupling ...
We demonstrate that this tag reports agonist-induced conformational changes in the receptor, with agonists causing a decline in the fluorescence intensity of ...
[34]
The Molecular Basis of G Protein–Coupled Receptor Activation - PMC
A general feature of agonist binding relative to inverse agonists is a small compaction of the orthosteric ligand–binding site arising from inward movements of ...
[35]
Structural Basis for Ligand Binding and Specificity in Adrenergic ...
Neutral antagonists do not change the basal activity of the receptor (zero efficacy), and inverse agonists are able to stabilize the inactive state of the ...
[36]
Structural Basis of Partial Agonism at the β2-Adrenergic Receptor
Dec 31, 2018 · ... orthosteric binding pocket, similar to the native agonist epinephrine. ... This outward movement of TM6 is considered one of the hallmarks of ...Special Issue · Figure 1 · Figure 3
[37]
Functionally Different Agonists Induce Distinct Conformations in the ...
Jan 1, 2001 · The agonist ISO and the partial agonist DOB both induce an intermediate state, R′, as well as distinct G protein-activating conformations R ...
[38]
Current Developments on the Role of α1-Adrenergic Receptors in ...
They play a key role in the regulation of the sympathetic nervous system along with β and α2-AR family members.
[39]
(PDF) The α1-adrenergic receptors: Diversity of signaling networks ...
The α(1)-adrenergic receptor (AR) subtypes (α(1a), α(1b), and α(1d)) mediate several physiological effects of epinephrine and norepinephrine.<|separator|>
[40]
ADRA1A adrenoceptor alpha 1A [Homo sapiens (human)] - Gene
Sep 5, 2025 · ... ADRA1A in Genome Data Viewer. Location: 8p21.2. Exon count: 11 ... Chromosome 8 - NC_000008.11 Genomic Context describing neighboring genes ...
[41]
ADRA1B adrenoceptor alpha 1B [Homo sapiens (human)] - Gene
Aug 19, 2025 · ... ADRA1B in Genome Data Viewer. Location: 5q33.3. Exon count: 10 ... Chromosome 5 - NC_000005.10 Genomic Context describing neighboring genes ...
[42]
https://pmc.ncbi.nlm.nih.gov/articles/PMC8185284/
[43]
Cardiac a1-adrenergic drive in pathological remodelling
Agonist stimulation of a1-ARs causes activation of Gq and phospholipase Cb (PLCb), resulting in hydrolysis of the sarcolemmal phospholipid, phosphatidylinositol ...
[44]
The Role of G Protein-Coupled Receptors (GPCRs) and Calcium ...
The α1 receptors through the Gq signaling pathway increase PLC activity and generate IP3 and DAG to amplify intracellular calcium mobilization [71]. All ...3. Dopaminergic Receptors · 7. Glutamate Metabotropic... · 9. Chemokine Receptors
[45]
α1-Adrenergic Receptor Subtypes | Circulation Research
α 1 ARs are activated by the catecholamines, norepinephrine and epinephrine. They are intrinsic membrane glycoproteins and are members of the GPCR superfamily.
[46]
Adrenergic G protein-coupled receptors in liver physiology ... - Nature
Oct 24, 2025 · This figure illustrates the distribution of different adrenergic receptors (α1-AR, α2-AR, β1-AR, β2-AR, β3-AR) in various liver cell types and ...
[47]
α1-Adrenergic Receptors: Insights into Potential Therapeutic ...
Feb 20, 2023 · α1-ARs regulate blood pressure through IP-mediated increased calcium release, causing the contraction of the vascular smooth muscle by ...
[48]
Structural basis of agonist specificity of α 1A -adrenergic receptor
Aug 10, 2023 · For example, the α1A-AR subtype is a vasopressor expressed in resistance arteries and is required for normal arterial blood pressure regulation.Missing: hypertension | Show results with:hypertension
[49]
Alpha-2 Adrenergic Receptor Agonists: A Review of Current Clinical ...
The α-2 receptors constitute a family of G-protein–coupled receptors with 3 pharmacological subtypes, α-2A, α-2B, and α-2C. Endogenous agonists, such as ...Missing: Gi/ o
[50]
Structural insights into ligand recognition, activation, and signaling ...
Mar 4, 2022 · The α2 adrenoceptors modulate a wide range of physiological functions, including the heart rate, blood pressure, regulation of blood glucose, ...
[51]
Pancreas-Brain Crosstalk - PMC - PubMed Central
Overexpression of the α2-adrenergic receptor on the β-cells is known to impair insulin granule docking at the plasma membrane, reduce β-cell exocytosis and ...
[52]
Adrenergic control of vascular resistance varies in muscles ... - NIH
Within the resistance vasculature of skeletal muscle there are α2-adrenergic receptors located on both the smooth muscle and vascular endothelium (for a review ...
[53]
Substitution of a mutant α2a-adrenergic receptor via “hit and run ...
The present study provides definitive evidence that the α2A subtype of α2AR mediates clinically relevant sedative-hypnotic, analgesic, and anesthetic-sparing ...
[54]
Structural determinants of the alpha2 adrenoceptor subtype selectivity
α2b-AR subtype is distributed mainly in peripheral tissues and mediates important physiological responses, such as salt-induced hypertension, vasoconstrictor ...
[55]
Clinical Considerations of Heritable Factors in Common Heart Failure
Because the β1-adrenergic receptor constitutes ~80% of all β-receptors ... Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular ...
[56]
β-Adrenergic receptor signaling in cardiac function and heart failure
Activated PKA then phosphorylates troponin I, the L-type Ca2+ channel and phospholamban (PLB), resulting in greater contractility (8).. In addition to Gs ...<|control11|><|separator|>
[57]
Inotropes and Vasopressors - StatPearls - NCBI Bookshelf - NIH
Beta-1 receptors have mostly positive chronotropic (heart rate) and inotropic (contractility) effects on the heart. Beta-2 receptors act as vasodilators in ...Inotropes And Vasopressors · Indications · Mechanism Of Action
[58]
153 - Gene ResultADRB1 adrenoceptor beta 1 [ (human)] - NCBI
Sep 5, 2025 · The ADRB1 (Adrenoceptor Beta 1) and ADRB2 genes significantly co-express with commonly mutated genes in prostate cancer. Influence of ADRB1, ...
[59]
Entry - *109630 - BETA-1-ADRENERGIC RECEPTOR; ADRB1 - OMIM
The ADRB1 gene encodes the B1 adrenergic receptor, which is coupled to G proteins and stimulates the intracellular production of cAMP.Missing: β1- | Show results with:β1-
[60]
Pharmacogenetic associations of β1-adrenergic receptor ...
Functional polymorphisms (Ser49Gly and Arg389Gly) in ADRB1 have been associated with cardiovascular and β-blocker response outcomes.
[61]
Biased agonism at β-adrenergic receptors - PMC - PubMed Central
Here we discuss the compounds identified to date that preferentially activate a G s - or β-arrestin-mediated signaling pathway through βARs.
[62]
β-arrestin–biased signaling through the β2-adrenergic receptor ...
Jun 27, 2016 · We report a β-arrestin–biased pepducin of the β 2 AR that is able to induce cardiomyocyte contractility and antiapoptotic signaling.
[63]
β 2 -adrenoceptor - IUPHAR/BPS Guide to PHARMACOLOGY
Transgenic (TG) mice overexpressing the β2-adrenoceptor in airway smooth muscle exhibit enhanced β2 signalling and an increase in basal cAMP levels. Tracheal ...
[64]
Beta2 Receptor Agonists and Antagonists - StatPearls - NCBI - NIH
B2 adrenergic receptors are coded on chromosome 5 and expressed predominantly in the smooth muscle cells of the airways. The receptor is composed of 8 alpha ...Missing: liver | Show results with:liver
[65]
Role of β-adrenergic receptors in regulation of hepatic fat ... - NIH
We demonstrate an increase in hepatic lipid content during senescence and a significant correlation between hepatic fat content and stimulation of adenylyl ...
[66]
G protein–coupled receptor kinases (GRKs) orchestrate biased ...
Aug 21, 2018 · These data suggest that G protein–biased signaling is driven more by an inability to recruit GRKs than by an inability to couple to β-arrestins.G Protein--Coupled Receptor... · Materials And Methods · β-Arrestin--Mediated...<|separator|>
[67]
Everything You Always Wanted to Know about β3-AR * (* But Were ...
β3-AR is abundantly expressed in rodent white (WAT) and brown (BAT) adipose tissue where it mediates lipolysis and thermogenesis [13,102]. In humans, β3-AR mRNA ...
[68]
Beta-3 Adrenergic Receptor | Encyclopedia MDPI
Unlike in β1- and β2-AR, it lacks sites for phosphorylation by protein kinase A (PKA) and β-adrenoceptor kinase (βARK) thereby making β3-AR relatively resistant ...<|control11|><|separator|>
[69]
β-Adrenergic Receptors and Adipose Tissue Metabolism
Feb 10, 2022 · The role of β-adrenergic receptors (βARs) in adipose tissue to promote lipolysis and the release of fatty acids and nonshivering thermogenesis ...Missing: structure | Show results with:structure
[70]
The β3‐Adrenergic Receptor: Structure, Physiopathology of Disease ...
Nov 28, 2024 · In humans, β1- and β2-adrenoceptors are the principal regulators of cardiovascular function, respectively, constituting ∼80% and ∼20% of all β- ...<|control11|><|separator|>
[71]
β3-Adrenergic receptors regulate human brown/beige adipocyte ...
Jun 8, 2021 · This study highlights that β 3 -ARs in human brown/beige adipocytes are required to maintain multiple components of the lipolytic and thermogenic cellular ...Missing: structure | Show results with:structure
[72]
Indispensable role of mitochondrial UCP1 for antiobesity effect of β 3
Treatment of obese animals with β3-adrenergic agonists is known to increase lipid mobilization, induce UCP1, and, finally, reduce body fat content.
[73]
Mirabegron: A Beta-3 Agonist for Overactive Bladder - PMC - NIH
Dec 1, 2015 · Mirabegron works via the sympathetic nerve pathway and stimulates beta-3 receptors, causing smooth muscle relaxation in the bladder. The use of ...
[74]
Protein-Protein Interactions at the Adrenergic Receptors - PMC - NIH
The adrenergic receptors (AR) mediate the functional effects of catecholamines, like epinephrine and norepinephrine, by coupling to different signaling pathways ...
[75]
Subtypes of alpha 1- and alpha 2-adrenergic receptors - PubMed
Feb 1, 1992 · The adrenergic receptors are members of the superfamily of G protein-coupled receptors. There are three major types of adrenergic receptors ...<|separator|>
[76]
Alpha 1-adrenergic Receptor Regulation: Basic Science ... - PubMed
Alpha 1ARs are G-protein-coupled receptors with three subtypes. They are regulated at mRNA and protein levels, and their activity is sensitive to structure.
[77]
Coupling of the alpha 2A-adrenergic receptor to multiple G-proteins ...
Feb 25, 1994 · In the present study, we have used a transient co-expression approach to study the coupling of a single alpha 2-adrenergic receptor (alpha 2AAR) ...
[78]
Simultaneous coupling of alpha 2-adrenergic receptors to two G ...
Aug 5, 1992 · Coupling of the three alpha 2-adrenergic receptor (alpha 2AR) subtypes to Gi and Gs was studied in membranes from transfected CHO cells.
[79]
Contribution of ligand structure to activation of alpha 2-adrenergic ...
Thus, the coupling of alpha 2AR subtypes to Gs occurs with endogenous catecholamines as well as multiple synthetic agonists, and the degree of Gs coupling is ...
[80]
Structure of the β1-Adrenergic Receptor-Gs Protein Complex
Oct 1, 2020 · Upon agonist stimulation, the β1AR primarily couples to the stimulatory subtype of heterotrimeric G-proteins (Gs) resulting in increased cAMP ...
[81]
Regulation of β-adrenergic receptor function - PubMed Central - NIH
In our current review we provide an overview on regulation of βAR function with a special emphasis on receptor resensitization and its functional relevance.
[82]
re-understanding the selectivity of β 1-adrenergic receptor to G protein
Aug 25, 2022 · This review summarizes the discovery of β 1 -AR-Gi pathway, including the evidence that supports β 1 -AR's capability to couple Gi.
[83]
Complex roles of cAMP–PKA–CREB signaling in cancer - PMC
Nov 24, 2020 · Once activated, PKA phosphorylates its substrates, such as CREB, Raf, Bad and GSK3 [25–27], and then regulates gene expression, cell survival ...
[84]
Phosphorylation of Ser 1928 mediates the enhanced activity of the L ...
Jan 24, 2017 · Qian et al. found that enhancement of Ca v 1.2 channel activity in the brain by β-adrenergic receptor (βAR) signaling required phosphorylation of Ser 1928.
[85]
CREB-binding protein (CBP) regulates β-adrenoceptor (β-AR) - Nature
Apr 12, 2013 · Here we demonstrate that the β-adrenoceptor/cAMP/PKA pathway triggers apoptosis through the transcriptional induction of the pro-apoptotic BH3-only Bcl-2 ...
[86]
Identification of the G protein-coupled receptor kinase ... - PubMed
Jun 7, 1996 · Rapid desensitization of G protein-coupled receptors is mediated, at least in part, by their phosphorylation by the G protein-coupled receptor ...
[87]
β-Arrestin Binding to the β2-Adrenergic Receptor Requires Both ...
Homologous desensitization of β2-adrenergic receptors has been shown to be mediated by phosphorylation of the agonist-stimulated receptor by G-protein-coupled ...
[88]
GPCR Signaling: β-arrestins Kiss and Remember
Apr 4, 2016 · A new study now reports that b-arrestin 2 is sufficiently. 'primed' after 'kissing' the b1-adrenergic receptor to initiate ERK activation even ...
[89]
Unique Positive Cooperativity Between the β-Arrestin–Biased β ...
Jan 2, 2025 · We recently identified compound-6 (cmpd-6), the first small molecule positive allosteric modulator of the β2-adrenergic receptor (β2AR). Cmpd-6 ...
[90]
Identification of a β-arrestin-biased negative allosteric modulator for ...
This work thus identifies an allosteric modulator capable of effecting Gs-biased β2AR signaling and suggests the clinical utility of biased ligand ...
[91]
The α1D-adrenergic receptor directly regulates arterial blood ... - NIH
We conclude that the α1D-AR participates directly in sympathetic regulation of systemic blood pressure by vasoconstriction.
[92]
Are the pharmacology and physiology of α2adrenoceptors ...
All three α2-adrenoceptor subtypes are coupled to G-proteins of the Gαi/o family and therefore share general signalling properties (Limbird, 1988). α2- ...
[93]
Regulation of β-Adrenergic Receptors in the Heart - PubMed Central
In this narrative review, we focus on the regulation of β-ARs at the receptor, G protein, and effector loci, as well as their signal transductions in the ...2.2. β-Ar Signaling · 4. Role Of G Protein And Ac... · 4.3. Adenylyl Cyclase (ac)
[94]
α-Adrenergic receptor regulation of skeletal muscle blood flow ...
During dynamic exercise, SNS activity increases in an effort to redistribute blood flow and optimize perfusion of the exercising skeletal muscle (41).
[95]
Beta2-Agonists - StatPearls - NCBI Bookshelf - NIH
Beta-2 adrenergic receptor agonists are a class of medications used in the frontline management and treatment of bronchial asthma and COPD.Missing: liver | Show results with:liver
[96]
[PDF] Adrenergic Agonist and Antagonist Action in Airways of Patients with ...
Nov 10, 2011 · Results gained in vivo shows that stimulation of alpha adrenergic receptor with dopamine (4 µg and 300 µg) causes significant contraction (p > ...
[97]
β3-Adrenergic receptors regulate human brown/beige adipocyte ...
Jun 8, 2021 · This study highlights that β 3 -ARs in human brown/beige adipocytes are required to maintain multiple components of the lipolytic and thermogenic cellular ...
[98]
Overexpression of β2-adrenergic receptors in mouse liver alters the ...
The hepatic β2-adrenergic system plays an important role in the maintenance of blood glucose homeostasis via glycogenolysis and gluconeogenesis. Because ...
[99]
Genetics of β2-Adrenergic Receptors and the Cardiopulmonary ...
In addition to increased alveolar ventilation and cardiac output, the regulation of blood flow distribution during exercise is important, and flow is shunted ...Missing: redistribution | Show results with:redistribution
[100]
Adrenergic Receptor Protein in Human Myometrium with Labor
A considerable body of evidence exists suggesting that the β2-adrenergic receptor (β2-AR) mediates uterine relaxation. However, little information exists on the ...
[101]
Review Drugs acting on the pregnant uterus - ScienceDirect.com
There is a large body of evidence supporting the use of β2-adrenergic receptor (β2-AR) agonists for the treatment of preterm labour, as they decrease the number ...
[102]
α2-Adrenoceptor-Mediated Hyperpolarization of Locus Coeruleus ...
These results suggest that a hyperpolarization of membrane potential mediated by an α2-adrenoceptor underlies both clonidine- and activation-induced inhibition ...
[103]
Noradrenergic Modulation of Wakefulness/Arousal - PMC
The locus coeruleus, and likely other noradrenergic nuclei, exert potent wake-promoting actions via an activation of noradrenergic β- and α 1 -receptors.Wake/arousal-Promoting... · Neurocircuitry And Receptor... · Wake-Promoting Actions Of Ne...
[104]
β-Adrenergic Control of Hippocampal Function - PubMed Central - NIH
NA acting on β-adrenergic receptors (β-AR) is a key determinant as to whether new experiences result in persistent hippocampal synaptic plasticity.
[105]
Astrocytic β2-adrenergic receptors mediate hippocampal long-term ...
Jul 8, 2016 · Here we show that astrocytic rather than neuronal β 2 ARs in the hippocampus play a key role in the consolidation of a fear-based contextual memory.
[106]
Cellular and subcellular distributions of β1- and β2-Adrenoceptors in ...
β-Adrenoceptors (ARs) in the hippocampus play an important role in regulating synaptic plasticity and memory consolidation. However, little is known about ...
[107]
Alpha2 adrenergic agonists for attention deficit hyperactivity disorder ...
Alpha2 agonists are medications that stimulate alpha2 adrenergic receptors in various parts of the nervous system, particularly the prefrontal cortex. Of these, ...
[108]
Neural circuits regulating visceral pain | Communications Biology
Apr 13, 2024 · The LC noradrenergic system is the main source of noradrenaline in the central nervous system and is involved intensively in modulating pain, ...
[109]
Role of α1-Adrenoceptor Subtypes in Pupil Dilation Studied ... - IOVS
The α 1A -adrenoceptor (α 1A -AR) subtype was suggested to mediate contraction and trophic effects in the iris dilator muscle.
[110]
Beta3-adrenoceptors in urinary bladder - PubMed
Beta(3)-AR agonists increase bladder capacity without influencing bladder contraction and have only weak cardiovascular side effects.
[111]
Central Nervous System Control of Gastrointestinal Motility and ...
The sympathetic nervous system exerts a predominantly inhibitory effect upon GI muscle and provides a tonic inhibitory influence over mucosal secretion while, ...
[112]
Alpha-Blockers - StatPearls - NCBI Bookshelf - NIH
Feb 6, 2025 · Doxazosin, prazosin, and terazosin are examples of selective alpha-1 adrenergic antagonists used for essential hypertension, although they ...
[113]
The affinity and selectivity of α‐adrenoceptor antagonists ...
Feb 27, 2022 · Yohimbine, RX821002, RS79948, and atipamezole are high affinity non-selective α2-antagonists. BRL44408 was the most α2A-selective antagonist, ...
[114]
Beta Blockers - StatPearls - NCBI Bookshelf
Beta-1 receptor-selective blockers like atenolol, bisoprolol, metoprolol, and esmolol only bind to the beta-1 receptors; therefore, they are cardio-selective.
[115]
A Systematic Review of Inverse Agonism at Adrenoceptor Subtypes
As many, if not most, ligands at G protein-coupled receptor antagonists are inverse agonists, we systematically reviewed inverse agonism at the nine4.3. β-Ar · 5.3. β-Ar · 5.3. 1. Heart<|control11|><|separator|>
[116]
https://www.ncbi.nlm.nih.gov/books/NBK556066/
[117]
Metoprolol - StatPearls - NCBI Bookshelf
Feb 29, 2024 · Metoprolol is indicated primarily for conditions such as hypertension, angina pectoris, heart failure, and arrhythmias.
[118]
Metoprolol: MedlinePlus Drug Information
Sep 15, 2023 · Metoprolol is used alone or in combination with other medications to treat high blood pressure. It also is used to treat chronic (long-term) angina (chest pain ...
[119]
Tamsulosin: a review of its pharmacology and therapeutic efficacy in ...
Tamsulosin is effective in patients with mild to severe LUTS associated with BPH, in patients with diabetes mellitus and in the elderly, and does not interfere ...
[120]
Long-term efficacy and safety of tamsulosin for benign prostatic ...
Of patients completing 6 years of treatment, 80.7% demonstrated consistent positive response with extremely low incidence of orthostasis.
[121]
Albuterol - StatPearls - NCBI Bookshelf
Jan 10, 2024 · Albuterol is a commonly prescribed bronchodilator used for managing diverse respiratory conditions, including asthma and exercise-induced bronchospasm.
[122]
Clonidine - StatPearls - NCBI Bookshelf
Clonidine is a 40-year-old antihypertensive medication that acts as an agonist on alpha-adrenergic and imidazoline receptors. Clonidine is an ...
[123]
Adrenaline in the Acute Treatment of Anaphylaxis - PMC
Aug 6, 2018 · The anti-anaphylactic effect of adrenaline/epinephrine is primarily due to the stimulation of alpha and beta receptors. The alpha adrenergic ...
[124]
Tamsulosin-Induced Atrial Fibrillation With Rapid Ventricular ... - NIH
Jun 7, 2022 · By recognizing tamsulosin as a cause of orthostatic hypotension, which can induce reflex tachyarrhythmias, emergency medicine physicians may not ...
[125]
Mirabegron - StatPearls - NCBI Bookshelf
Aug 28, 2023 · It received approval from the US Food and Drug Administration (FDA) in June 2012 for treating overactive bladder with symptoms of urge urinary ...<|control11|><|separator|>
[126]
β-Adrenoceptor polymorphisms and heart failure - ScienceDirect.com
Many polymorphisms have been described for the genes encoding the β1-, β2- and α2C-adrenoceptors that result in altered signaling and/or regulatory ...
[127]
Association of Genetic Polymorphisms in the Beta-1 Adrenergic ...
Feb 12, 2019 · ADRB1 Ser49Gly, but not Arg389Gly, was significantly associated with recovery of LVEF in patients with HFrEF. HFrEF patients that were ...
[128]
Influence of Beta-1 Adrenergic Receptor Genotype on ... - NIH
Dec 7, 2018 · ... 80% of the cardiac ... Myocardial Recovery in Patients With Systolic Heart Failure and Autoantibodies Against beta1-Adrenergic Receptors.
[129]
Polymorphisms of cardiac presynaptic α 2C adrenergic receptors
In addition, we have shown (5) that the α2CDel322-325 is an independent risk factor for the development of heart failure in African Americans (odds ratio ≈5 ...
[130]
A meta‐analysis of the influence of ADRB2 genetic polymorphisms ...
Sep 28, 2020 · Synthesis of the studies to date shows weak evidence for an association between ADRB2 Arg16Gly and Gln27Glu and FEV1.0% after albuterol use.
[131]
Genetics of attention deficit hyperactivity disorder - Nature
Jun 11, 2018 · A meta-analysis covering all genetic association studies of adults with ADHD reported a significant association between adult ADHD and BAIAP2 ( ...Missing: post- | Show results with:post-
[132]
Structure-based discovery of nonopioid analgesics acting through ...
Sep 30, 2022 · Of particular interest is the α2A-adrenergic receptor (α2AAR), a G protein–coupled receptor (GPCR) whose activation in the central nervous ...
[133]
How carvedilol does not activate β 2 -adrenoceptors - Nature
Nov 30, 2023 · Patients who begin taking carvedilol do not develop a tachycardia, and indeed, lowering heart rate in heart failure can be beneficial. Several ...
[134]
Beta-Arrestins in the Treatment of Heart Failure Related to ... - NIH
Jun 5, 2021 · The drug carvedilol is a weak β-arrestin-biased agonist which works by activating extracellular signal-regulated kinases (ERKs) via EGFR ...
[135]
Regulation of β-Adrenergic Receptors in the Heart - MDPI
In addition, carvedilol functions as a β-arrestin-biased agonist at the β2-AR while acting as an inverse agonist by inhibiting Gαs protein signaling, which ...
[136]
Optogenetic Stimulation of Locus Ceruleus Neurons Augments ...
Apr 30, 2014 · In this study, we test directly the hypothesis that activation of noradrenergic neurons in the LC influences CVNs using optogenetic activation ...
[137]
The Noradrenergic System in Parkinson's Disease - Frontiers
Apr 7, 2020 · Regarding changes in adrenergic receptors in PD, an in vitro autoradiographic study showed upregulation of α1- and β1- and reduced density of α2 ...
[138]
Evolutionary diversification and expressional profile of adrenergic ...
Oct 23, 2025 · Motif analysis of AR genes has revealed the presence of conserved structural elements across species, accompanied by notable evolutionary ...
[139]
Neurobiology of Cancer: The Role of β-Adrenergic Receptor ...
We provide a new complex view of the role of β-adrenergic receptor signaling within the tumor micro- and macroenvironments as well as in mediating the effects ...
[140]
β2‐adrenergic receptor signaling drives prostate cancer progression ...
In this study, we uncovered an important role of β 2 ‐AR signaling in regulating the Shh pathway activity in PCa tumorigenesis.
[141]
the pharmacogenomics of adrenergic receptor signaling
Pharmacogenomics is the study of genetic contributions to drug response variability in order to provide evidence for a tailored therapy in an individual patient ...
[142]
Incretin-based therapies for the treatment of obesity-related diseases
Nov 6, 2024 · Mirabegron, a beta3-adrenoceptor agonist, is currently under investigation as an alternative strategy to achieve weight loss by inducing ...
[143]
May 2024 - Atrogi
May 24, 2024 · Atrogi's lead compound, ATR-258 for T2D, completed a Phase 1a/b clinical trial in March 2024, with Phase II trials planned by the end of 2024.